News
Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...
Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...
Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback